1. Introduction {#sec0005}
===============

Pathologic changes in tendons due to repetitive use are a significant cause of morbidity in athletic humans and horses ([@bib0045; @bib0195; @bib0385]). The importance of inflammation in both the pathogenesis of tendon injury and the healing process has been contentious in recent years and is poorly understood. Equine clinicians are familiar with the clinical signs of inflammation immediately after a tendon injury occurs, but these signs are not so evident during the chronic phase of injury. Overstrain injury in humans is generally considered to result from a primarily degenerative condition where clinical signs of inflammation and invading inflammatory cells are rarely observed ([@bib0010; @bib0030; @bib0165; @bib0170; @bib0175; @bib0420]). However, this lack of perceived clinical inflammation may be attributable to factors such as the later presentation of human patients, frequently with recurrent injury and the availability of tissues for analysis at different times after injury. Furthermore, the absence of clinically evident inflammation does not preclude an integral role for inflammatory mediators during the pathogenesis and healing of tendon injuries at a cellular level. Current controversy regarding the role of inflammation in tendon injury and healing is similar to that previously debated in joint disease. Use of the term 'arthritis' with its emphasis on inflammation, has generally replaced the term 'arthrosis' when referring to a wide variety of joint disease conditions ([@bib0040]). This change in terminology reflects the fact that inflammatory cytokines have recently been shown to play a pivotal role in the development of joint disease even when clinical signs of inflammation may not be detected. Terminology commonly used to refer to tendon pathology is further described in [Box 1](#tb0005){ref-type="boxed-text"}.

Several laboratory animal models have been used to investigate tendon injury; however, these induced injury models do not accurately reproduce the naturally occurring conditions that are detected in human and equine patients ([@bib0235]). Horses, on the other hand suffer a high frequency of clinical overstrain injury involving a wide spectrum of tendons and ligaments. Therefore the horse presents an attractive large animal model not only for equine related studies but also as a relevant model of human injury due to the shared characteristics of aging phenotypes ([@bib0095; @bib0365]), elastic energy storing function common to the weight-bearing tendons of both species ([@bib0180; @bib0430]) and injury induced by natural athletic activity. Equine tendon healing processes are traditionally classified into three distinct but overlapping phases in naturally occurring injury; the acute inflammatory phase occurs immediately after the initial trauma lasting only a few days, followed by the sub-acute reparative phase (peaking at 3--6 weeks but lasting several months and chronic remodelling phase (\>3 months after injury) ([@bib0090]). Whilst this temporally coordinated but overlapping sequence of events describes very well the clinical progression of SDFT lesions and other injuries such as some suspensory branch desmopathies in the horse, injuries to the human Achilles tendon manifest differently with less well defined phases characterised by persistent pain and 'failed healing' ([@bib0230]). These clinical descriptions of the healing phases suggest that inflammation drives acute and chronic phases of injury. However recent insights into the underlying molecular events suggest that some components of the inflammatory cascade are necessary for resolution of injury. This review will discuss the inflammatory mediators relevant to tendon disease and illustrate that in addition to pro-inflammatory roles, inflammation triggers important resolution processes, which can potentially be harnessed for beneficial therapeutic effect.

2. Inflammation related mediators in tendon health and disease {#sec0010}
==============================================================

2.1. Cytokines in tendinopathy {#sec0015}
------------------------------

Cytokines are small proteins with the ability to influence the biological activities of cells and operate in an autocrine/paracrine manner. They are highly potent and exert their effects at picomolar concentrations. The interaction between a cytokine and its receptor triggers a series of intracellular signalling events culminating in a physiological response ([@bib0105]). Cytokines are reported to have important roles in tendon and ligament homeostasis by regulating cellular differentiation and activity ([@bib0105; @bib0225; @bib0255]) and the synthesis of tendon matrix ([@bib0250; @bib0280; @bib0375]). However, samples of injured equine SDFT stain positively for pro-inflammatory cytokines IL-1α, IL-1β, TNF-α and IFN-γ which were not found in normal tendons ([@bib0145]). Hence in conjunction with their proposed homeostatic roles, cytokines are also potential contributors to the development of tendinopathy.

In addition to the study of natural tendon disease, rodent models of induced tendon injury and *in vitro* cell/tissue culture studies have been utilised to investigate the roles of cytokines in tendinopathy. Treadmill running of rats to simulate tendon overuse showed up-regulation of inflammation-related genes IL-11, IL-15, IL-6, TNF-α ([@bib0250]). The fatigue loading of rat patellar tendons produced structural changes accompanied by increased expression of both MMP-13 and IL-1 β ([@bib0375]). Furthermore, both repetitive cyclical stretching of tendon fibroblasts *in vitro* and stimulation with IL-1β induced MMP production and expression of COX-2 and PGE~2~ ([@bib0025; @bib0395; @bib0445]). Not only are cytokines associated with the onset of injury, the macrophages releasing these cytokines are potentially important for effective debridement and subsequent healing of the injured tendon. For example, healing was shown to be inferior in a surgical model of patellar tendon injury in IL-6 knockout mice, even though IL-6 has both pro and anti-inflammatory effects ([@bib0225]).

2.2. Prostaglandin lipid mediators in tendinopathy {#sec0020}
--------------------------------------------------

Prostaglandins also have potentially important roles in tendon health and disease. Prostaglandins are synthesised from arachadonic acid by COX-1 and COX-2. Arachadonic acid is in turn derived from the cell membrane phospholipid bilayer by the activity of phospholipase enzymes in response to trauma, cytokines and growth factors ([@bib0120]). Prostaglandins act in an autocrine or paracrine fashion at nanomolar concentrations ([@bib0360]). There are 3 series of prostaglandins; the 1 series prostaglandins give rise to PGE~1~ and PGF~1α~, 2 series prostaglandins include PGD~2~, PGE~2~ and PGF~2α~ and the 3 series prostaglandins PGE~3~ and PGF~3α~ ([@bib0005]). Prostaglandins of the 1 and 3 series are considered to be less biologically active than those of the 2 series ([@bib0150; @bib0200]). These lipid mediators exert their biological effects by binding to a series of receptors present on the surface of cell membranes. Multiple receptor subtypes have been identified in mice and humans, including the prostaglandin D receptors DP~1~, DP~2~ and the prostaglandin F receptor FP. A series of four Prostaglandin E (EP) receptor subtypes are responsible for mediating the downstream effects of PGE~2~, which include EP~1~, EP~2~, EP~3~ and EP~4~.

Constitutive prostaglandin production is a prerequisite for normal physiologic processes in many tissues and cells of the body including bone remodelling, modification of blood flow (both vasoconstriction or vasodilation), vascular permeability, smooth muscle tone and platelet aggregation ([@bib0100; @bib0140; @bib0270; @bib0290; @bib0425]). Prostaglandin production appears to be a normal physiologic response of tendon cells to repetitive motion. For example, PGE~2~ levels increased in the peri-tendinous Achilles region of healthy exercising humans ([@bib0205]) and in murine patellar and Achilles tendons following treadmill exercise ([@bib0455]). These observations are supported by *in vitro* experiments whereby tendon fibroblasts in culture release PGE~2~ in response to repetitive cyclic strain ([@bib0015; @bib0020; @bib0415]).

In addition to constitutive production, prostaglandins are produced in response to injury ([@bib0390]). PGE~2~ is released by tendon fibroblasts *in vitro* in response to stimulation with IL-1β in a COX-2 dependent manner ([@bib0395; @bib0445]) and the inducible terminal synthase of PGE~2~ (microsomal prostaglandin E synthase-1, mPGES-1) is also up-regulated by IL-1β ([@bib0160; @bib0190]). The role of prostaglandins in tendinopathy is complex and diverse with evidence supporting both deleterious and beneficial effects. Deleterious effects were observed after peri-tendinous injection of PGE~1~ into the rat Achilles tendon leading to increased tendon cross sectional area and degenerative changes similar to those observed in human tendinopathy after 5 weeks ([@bib0370]). Similarly, repeated intratendinous injection of 500 ng PGE~2~ into rabbit patellar tendons culminated in degenerative changes such as focal hyper cellularity, disorganised tissue architecture and reduced collagen fibril diameter compared with control tendons ([@bib0185]). This may be effectuated via the prostaglandin EP~4~ receptor that appears to mediate the degradative effects of IL-1 induced prostaglandins ([@bib0380]). In addition to IL-1, PGE~2~ potentiates ECM catabolism in cartilage, periodontal ligament ([@bib0035; @bib0285]) and tendon via increased expression of MMP-1 and MMP-3 mRNA ([@bib0380; @bib0395; @bib0445]) and proteins ([@bib0395]).

However, evidence also exists to support a positive role of PGE~2~ in tendon healing. Peri-tendinous injections of 800 ng PGE~2~ into the rat patellar tendon improved tendon mechanical properties compared to non-treated controls or saline-injected tendons ([@bib0110]). The role of PGE~2~ in equine tendons has not been extensively studied, although we have shown that higher doses of PGE~2~ countered the catabolic effects of IL-1β in an *in vitro* model of equine tendon inflammation ([@bib0070]). NSAIDs inhibit prostaglandin production and are widely used pharmacological agents for the treatment of inflammatory diseases and to alleviate the pain associated with tendinopathy. Despite evidence suggesting inflammation also having detrimental effects on the healing process of connective tissues, non-specific blockade of the inflammatory response may not necessarily be beneficial to the healing process ([@bib0240; @bib0245]). Inhibition of prostaglandin synthesis in tendon fibroblasts undergoing cyclical stretch *in vitro* results in a compensatory elevation in levels of the pro-inflammatory leukotriene B~4~, potentially exacerbating inflammation ([@bib0220]). Studies have revealed the potential for COX inhibitors to impair healing of tendons ([@bib0060; @bib0115]) and reduce exercise-induced increases in collagen synthesis in the human patellar tendon ([@bib0055]). Moreover PGE~2~ generated during inflammation, activates specialised pro-resolving lipid mediators such as lipoxins and resolvins, which are essential in restoring tissue homeostasis after inflammation or injury ([@bib0215; @bib0315; @bib0320]). Hence 'switching off' prostaglandins is likely to have a negative impact upon the body\'s endogenous mechanisms to regulate inflammation ([@bib0130; @bib0295]).

Prostaglandins also exhibit immuno-modulatory properties, for example PGE~2~ down-regulates the inflammatory response via inhibiting production of pro-inflammatory IL-12 whilst stimulating production of the anti-inflammatory cytokine IL-10 ([@bib0400]). Hence prostaglandins such as PGE~2~ exhibit double-edged sword properties in terms of their perceived beneficial and detrimental effects on tendons. This may be influenced by the dose of PGE~2~ and experimental model used, however the concept of maintaining a balance to ensure regulation of prostaglandin production in tendons is likely to be of physiological importance.

2.3. Inflammation triggers resolution {#sec0025}
-------------------------------------

An intriguing dimension to the physiology of inflammation is the identification of specialised pro-resolving mediators (SPM) encompassing lipoxins such as lipoxin A~4~ (LXA~4~) ([@bib0325]) acting upon the resolving receptor FPR2/ALX ([@bib0450]) and more recently, the resolvins and maresins ([@bib0330; @bib0340]). FPR2/ALX is expressed by monocytes and macrophages ([@bib0440]) and is central in controlling the duration and magnitude of the inflammatory response, providing endogenous stop signals for inflammation ([@bib0335]). Resolution pathways are programmed responses activated during inflammation, resulting in a switch in lipid mediators from the dominance of prostaglandins to the lipoxins to promote resolution of inflammation and the return of tissues to their normal homeostatic state ([@bib0215; @bib0310; @bib0325; @bib0335]). Importantly, resolution has been shown to be an active and highly regulated physiological process ([@bib0300; @bib0305]) rather than simple passive cessation of inflammation as previously thought. Key events in resolution of inflammation include phagocytosis of apoptotic cells, modification of inflammatory cell infiltration to the inflamed site and modulation of vascular permeability ([@bib0300]). However, whilst resolution is well studied in experimental murine models of inflammation, there is limited information documenting this process in naturally diseased connective tissues and resolution has only recently been identified in injured equine tendons ([@bib0070; @bib0085]).

3. Recent developments on the role of inflammation in equine tendinopathy: implications for current clinical practice {#sec0030}
=====================================================================================================================

There is little published information that has addressed the role of inflammation in equine tendon disease. A persistent inflammatory stimulus with sustained production of growth factors, proteolytic enzymes and cytokines is a common feature of fibrotic diseases, stimulating the deposition of connective tissue elements that are detrimental to normal tissue architecture ([@bib0435]). Fibrosis is the final common pathogenic process for many forms of chronic inflammatory disease ([@bib0210]). Although the deposition of scar tissue is an integral component of the healing response, the altered composition of the tendon ECM compromises the structural and functional properties of tendons and potentially contributes towards the high risk of re-injury ([@bib0065; @bib0075]). Through the study of natural tendon injury in the horse, we have demonstrated that aberrations in the enzymes regulating PGE~2~ metabolism occur soon after injury ([@bib0070]). In addition, components of inflammation have also been shown to be highly active at this stage, demonstrated by the presence of M1 polarised macrophages (Mφ) ([@bib0085]), which release pro-inflammatory mediators such as IL-1β and PGE~2~. During the later phase of tendon healing, the M2Mφ phenotype predominates (releasing anti-inflammatory cytokines) and we have proposed that these cells are actively surveying the healing tendon for 'stress signals' to protect this susceptible region from re-injury.

The practice of using steroids and non-steroidal anti-inflammatory drugs (NSAIDs) to relieve pain associated with tendon injury is controversial. Whilst appropriate short term systemic use of these drugs is unlikely to be associated with deleterious patient side effects, prolonged use of NSAIDs or intratendinous injection of steroid preparations are associated with adverse effects on tendon mechanical properties ([@bib0410]) and propensity for rupture ([@bib0345]), respectively. Furthermore, adverse systemic effects of NSAIDs also include gastrointestinal ulceration ([@bib0405]), which occurs due to disruption of normal homeostatic mechanisms involving prostaglandin synthesis. Whilst the inflammatory component of tendinopathy has received much attention, the processes concerned with resolution of tendon inflammation have been neglected from a therapeutic perspective. Improved understanding of inflammation is crucial to the development of novel anti-inflammatory agents that preserve the beneficial, yet remove the detrimental components of the cascade. Although the field of resolving inflammation is relatively new, understanding of pro-resolution processes is rapidly evolving using murine models of experimentally induced inflammation ([@bib0265; @bib0275]). Inhibiting inflammation has been shown to 'switch off' the activation of key inflammation-resolving mechanisms ([@bib0130]). Harnessing the potential of pro-resolving mediators represents a new approach to managing inflammatory diseases in the future. Pro-resolving pathways have not been widely studied in injured tendons, although we have demonstrated increased expression of the pro-resolving receptor FPR2/ALX ([@bib0085]) and the switch from pro-inflammatory prostaglandins to the production of pro-resolving lipids such as LXA~4~ during the early stage of tendon injury ([@bib0070]). However, it is hypothesised that this resolving response is somehow dysregulated or of insufficient duration or magnitude, as tendon inflammation is not adequately 'switched off' ([@bib0085]). This favours the development of chronic inflammation and the formation of a fibrogenic repair scar ([Fig. 1](#fig0005){ref-type="fig"}). In support of this concept, expression of the pro-resolving receptor FPR2/ALX (a critical component in mediating pro-resolving mechanisms) has been shown to reduce with time after tendon injury and with ageing ([@bib0070]). This is likely to have implications for sustaining chronic tendon injury if acute inflammation is insufficiently resolved, and in the development of re-injury with age because the ability to resolve tendon inflammation diminishes with ageing.

4. Conclusions {#sec0035}
==============

Selectively managing tendon injuries according to their disease stage is likely to be an important aspect determining the success of therapy. Future therapeutic management of early stage tendon injury may require addressing both sides of the inflammation equation, whereby inflammatory processes can be modulated to prevent inappropriate or prolonged ECM degradation, whilst simultaneously enhancing pro-resolving processes. In the chronic stage of tendon disease it may be more appropriate to avoid the use of NSAIDs due to their perceived adverse effects on collagen synthesis ([@bib0055]). Instead, treatment of chronic tendon injury could focus on promoting pro-resolution processes by guiding chronically inflamed tissues into a resolving pathway. This may be accomplished by addressing novel therapeutic targets such as pro-resolving lipids or proteins ([@bib0125; @bib0135; @bib0260]), which may be beneficial in reducing the propensities for fibrotic tendon healing and re-injury.

The capacity to prevent tendon injury remains the ultimate goal; however this is currently precluded by our inability to accurately identify sub-clinical injuries *in vivo*. Sub-clinical injuries are attributable to the effects of exercise and have been identified during post mortem examination of equine SDFTs ([@bib0050; @bib0350]). Future research should aim to identify parameters that determine the inflammatory status of injured tendons *in vivo*. This encompasses the development of biomarkers of tendon injury ([@bib0080; @bib0155; @bib0355]), which may facilitate identification of sub-clinical injuries prior to the onset of overt clinical disease. This review highlights the importance of a finely balanced inflammatory response in tendon healing. The recent identification of pro-resolving mediators in healing equine tendons provides novel therapeutic opportunities in the quest for effective prevention and treatment.
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![Schematic to propose the relationship between inflammation and resolution in the development of tendon injury. (A) In early stage injury, inflammation triggers a tendon resolution response, which appears to be transient and reduces with age and time after injury. During the later stages of healing (chronic injury) we propose that insufficient or dysregulated resolution allows low-level inflammation to persist, increasing the propensity for fibrotic healing and re-injury. (B) To improve the healing response of tendon, a potential therapeutic strategy is to moderate inflammation whilst simultaneously enhancing the tendons resolution response.](gr1){#fig0005}

###### Terminology

The terms below are used commonly in a variety of clinical scenarios but have not been well defined. For the purposes of this review, we have attempted to clarify what would be considered the most appropriate use of these terms.

'**Tendinopathy**' is used to describe disorders affecting tendons, including tendon rupture and chronic pain. This term does not assume any knowledge about the underlying pathology.

'**Tendonitis**' is used to describe a painful tendon and implies that tendon injury is accompanied by an inflammatory response.

'**Tendinosis**' is used to describe a painful tendon and implies that tendon injury develops as a consequence of a degenerative process and implies absence of inflammation.

'**Tendon disease**' implies that injury develops as a consequence of repetitive cyclic loading and the effects of ageing resulting in cumulative micro-damage. Often exacerbated by overstrain injury, the most common manifestation in the horse is a central core lesion.

'**Tendon injury**' encompassing tendon disease but also occurs as a consequence of traumatic injury when the tendon is lacerated after cutaneous injury.
